Bicifadine

DB04889InvestigationalSmall molecule

Bicifadine (DOV-220075) is a nonopioid analgesic. It is an inhibitor of both the norepinephrine and serotonin transporters and an NMDA antagonist with a non-narcotic profile. Bicifadine was shown to have... Bicifadine was shown to have potent analgesic activity in vivo and was chosen for further development for the treatment of pain.

Mechanism: Preclinical studies and clinical trials indicate that bicifadine's analgesic properties result through the enhancement and prolongation of norepinephrine and serotonin actions, however other actions may be involved.
Curator reviewed
Primary indication: For the treatment of pain.Curator reviewed
Formula / weight: C₁₂H₁₅N · 173.2542 g/mol (avg)
Code names: DOV-220075

Resolves to

Compound

UNIIB0SV3N7J3HCAS71195-57-8ChEMBLCHEMBL511099PubChem47953KEGGD03110

Structure

InChIKeyOFYVIGTWSQPCLF-UHFFFAOYSA-NSMILESCC1=CC=C(C=C1)C12CC1CNC2

Targets

P23975SLC6A2P31645SLC6A4P14416DRD2

What you can answer from here — as of August 30, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

569Drug interactionsStructured to mechanism, not free text

3Clinical trialsPhase, status and sponsor resolved per trial

11+ReferencesStructured and connected to the statements they support

Which drugs share a target with Bicifadine, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account